Ensuring Adherence in EGFR-Mutated NSCLC: Pharmacist Best Practices

This session highlights best practices for pharmacists to support adherence to various therapies in EGFR-mutated non–small cell lung cancer (NSCLC), including chemotherapy, tyrosine kinase inhibitors (TKIs), and antibody-based therapies. Panelists will discuss strategies to optimize patient understanding of dosing schedules, administration requirements, and potential side effects that may impact adherence. The role of pharmacists in patient education, counseling, and follow-up will be emphasized, as well as the importance of monitoring for drug–drug interactions and providing guidance on managing adverse events. Techniques for leveraging digital tools, adherence aids, and coordinated care approaches across the healthcare team will also be explored. By implementing these best practices, pharmacists play a critical role in ensuring patients maintain their treatment regimens, ultimately improving outcomes and supporting the safe, effective use of both targeted and conventional therapies in EGFR-driven NSCLC.